Gezielt nachschlagen
Suche
Suche startet nach einer kurzen Eingabepause.
20 angezeigte Treffer · Seite 3, keine Gesamtzahl für „NYHA“
Suchtreffer
Begriffe & Kennungen
Imraldi · 4.3 · Moderate to severe heart failure (NYHA class III/IV) (see section 4.4).
Eintrag öffnenKanjinti · 4.8 · Congestive heart failure (NYHA class II – IV) is a common adverse reaction associated with the use of trastuzu
Eintrag öffnenKanjinti · 4.8 · When trastuzumab was administered after completion of adjuvant chemotherapy NYHA class III-IV heart failure wa
Eintrag öffnenLesch-Nyhan-Syndrom
Eintrag öffnenLungenagenesie-Herzfehler-Daumenanomalien-Syndrom
Eintrag öffnenMvasi · 4.8 · In most clinical trials of bevacizumab, patients with pre-existing CHF of NYHA (New York Heart Association) II
Eintrag öffnenNezglyal · 4.3 · Cardiac failure or history of cardiac failure (NYHA stages I to IV) (see section 4.4).
Eintrag öffnenOgivri · 4.8 · Cardiac dysfunction Congestive heart failure (NYHA Class II – IV) is a common adverse reaction associated with
Eintrag öffnenOgivri · 4.8 · When trastuzumab was administered after completion of adjuvant chemotherapy NYHA Class III - IV heart failure
Eintrag öffnenOntruzant · 4.8 · Congestive heart failure (NYHA Class II-IV) is a common adverse reaction associated with the use of trastuzuma
Eintrag öffnenOntruzant · 4.8 · When trastuzumab was administered after completion of adjuvant chemotherapy NYHA Class III-IV heart failure wa
Eintrag öffnenOyavas · 4.8 · In most clinical trials of bevacizumab, patients with pre-existing CHF of NYHA (New York Heart Association) II
Eintrag öffnenPerjeta · 4.8 · In APHINITY, the incidence of symptomatic heart failure (NYHA class III or IV) with a LVEF decline of at least
Eintrag öffnenPerjeta · 4.8 · In the neoadjuvant period of the BERENICE trial, the incidence of NYHA Class III/IV symptomatic LVD (congestiv
Eintrag öffnenPhesgo · 4.8 · In APHINITY, the incidence of symptomatic heart failure (NYHA class III or IV) with a LVEF decline of at least
Eintrag öffnenPhesgo · 4.8 · In the neoadjuvant period of the BERENICE trial, the incidence of NYHA Class III/IV symptomatic LVD (congestiv
Eintrag öffnenPhesgo · 4.8 · In the pivotal trial FEDERICA, the incidence of symptomatic heart failure (NYHA class III or IV) with a LVEF d
Eintrag öffnenPoherdy · 4.8 · In APHINITY, the incidence of symptomatic heart failure (NYHA class III or IV) with a LVEF decline of at least
Eintrag öffnenPoherdy · 4.8 · In the neoadjuvant period of the BERENICE trial, the incidence of NYHA Class III/IV symptomatic LVD (congestiv
Eintrag öffnenRemicade · 4.3 · Patients with moderate or severe heart failure (NYHA class III/IV) (see sections 4.4 and 4.8).
Eintrag öffnen